10 May 2020
Posted in Coronavirus
Cerus Endovascular continues expanding aneurysm treatment portfolio amid COVID-19 pandemic
Cerus Endovascular’s secured CE approval for coil-assisted flow diverter Neqstent was a great win for the company, but the path ahead may be slow-going. GlobalData, a leading data and analytics company, expects that the device may experience a slower uptake due to the pandemic.
Sheryl Tang, Medical Device Analyst at GlobalData, comments: “When Cerus Endovascular entered the aneurysm market in February 2020, receiving CE approval for its Contour Neurovascular System, GlobalData expected the coil-assisted stent market to grow at a compound annual growth rate (CAGR) of approximately 3.8% in the forecast period. However, due to COVID-19, the endovascular treatment for aneurysms has reduced by at least 40% as a result of the suspension of elective procedures.
“Cerus Endovascular plans on a slow commercial market release across Europe toward the end of this year. GlobalData expects that, while many of the European countries that have been impacted heavily by COVID-19 reach their peak in April and May, the uptake of Cerus Endovascular’s Neqstent and Contour devices will experience a slow start. In addition to the general slow re-introduction of non-essential procedures, Cerus will have to compete against major competitors who have larger portfolios and distribution networks resulting in a faster recovery in the market.”